Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: silicified microcrystalline cellulose; maize starch; croscarmellose sodium; magnesium stearate - flecainide mlabs is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide mlabs should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide mlabs tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; silicified microcrystalline cellulose - flecainide mlabs is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide mlabs should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide mlabs tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hyphens pharma sdn. bhd. - ulipristal acetate; ulipristal acetate -

Israel - English - Ministry of Health

intervet ( israel) ltd - flugestone acetate - sponge - flugestone acetate 20 mg - in ewe and ewe lambs, in combination with pmsg (pregnant mare serum gonadotrophin):induction and synchronisation of oestrus and ovulation (non-cycling ewes during seasonal anoestrus and ewe lambs).synchronization of oestrus ovulation (cycling ewes and ewe-lambs).

Malta - English - Medicines Authority

opella healthcare france sas t/a sanofi 157 avenue charles de gaulle, 92200 neuilly-sur-seine , france - aluminium hydroxide, magnesium hydroxide - oral suspension - aluminium hydroxide 460 mg magnesium hydroxide 400 mg - drugs for acid related disorders

Australia - English - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - eslicarbazepine acetate, quantity: 800 mg - tablet, uncoated - excipient ingredients: magnesium stearate; croscarmellose sodium; povidone - zebinix is indicated as:,? monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;,? adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - eslicarbazepine acetate, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; croscarmellose sodium - zebinix is indicated as:,? monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;,? adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.

United States - English - NLM (National Library of Medicine)

gland pharma limited - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. limitations of use: desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% without factor viii antibodies to: -  maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. desmopressin acetate injection is indicated for patients with mild to moderate von willebrand’s disease (type i) with factor viii levels greater than 5% to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - difelikefalin acetate, quantity: 55 microgram (equivalent: difelikefalin, qty 50 microgram) - injection, solution - excipient ingredients: sodium chloride; sodium acetate trihydrate; acetic acid; water for injections - korsuva is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

Kenya - English - Pharmacy and Poisons Board

cosmos limited rangwe road, off lunga lunga road, industrial - dried aluminium hydroxide bp - chewable tablet - 500mg - aluminium antacids compounds